NCT00709878View on ClinicalTrials.gov

Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors

CompletedOBSERVATIONAL
Enrollment

32

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Skin Rash
Interventions
PROCEDURE

Skin Biopsy of Skin Rash Secondary to EGFRI Use

Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.

Trial Locations (1)

60611

Northwestern University, Chicago

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Northwestern University

OTHER

NCT00709878 - Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors | Biotech Hunter | Biotech Hunter